# Vimta Labs share price today (Vimta Labs Ltd, NSE: VIMTALABS)

> Vimta Labs share price today: ₹485.55 at the NSE close on 3 November 2026, down 33.1% in a year. Vimta Labs (NSE: VIMTALABS) is worth ₹2,170 crore, trades at a P/E of 26.6 and has closed between ₹401.35 and ₹657.80 over the past 52 weeks. > Vimta Labs Ltd's earnings have grown faster than its share price. Earnings per share grew +14.7% in a year while the price moved −33.1%. VIMTALABS · Diagnostics · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/vimta-labs-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: ₹485.55 (−33.1% in a year)
- P/E: 26.6× (higher than 54% of the last 10 years)
- Revenue (Sep 2026): ₹112 Cr (+9.8% on a year ago)
- Profit (Sep 2026): ₹21.0 Cr (+5.0% on a year ago)
- Operating margin: 34.0% (flat on a year ago)
- ROCE: 25%, FY26
- ROIC: 19.1%, against a 12.0% cost of capital: +7.1 points

The main question: yearly earnings per share moved +14.7% while the share price moved −33.1%. ## What is the Vimta Labs share price today? Vimta Labs Ltd's share price was ₹485.55 at the close on 3 November 2026. It has been rising for 16 weeks. That is 12.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹401 and ₹658, and at that close it sat 33% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running. Over the last 11 years the share price moved +1,282% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Vimta Labs this quarter? Three changes stood out: promoters cut their stake for 8 quarters in a row, revenue up on a year earlier for 9 quarters in a row and indian funds and insurers (DIIs) raised their stake for 3 quarters in a row. 1. Promoters cut their stake for 8 quarters in a row From 36.9% to 35.6% of the company by the September 2026 quarter. 2. Revenue up on a year earlier for 9 quarters in a row In the September 2026 quarter revenue was ₹112 crore, +9.8% on a year earlier. Why: Revenue rose because preclinical testing demand was strong and long-term analytical client work stayed steady. Next results: check whether clinical and food testing volumes improve in the stronger second half. From the earnings call on 30 Oct 2026. 3. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row From 0.1% to 0.5% of the company by the September 2026 quarter. ## What are Vimta Labs' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Vimta Labs reported revenue of ₹112 crore, up 9.8% from ₹102 crore a year earlier, and a profit of ₹21.0 crore, up 5.0% from ₹20.0 crore. ### Vimta Labs results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹112 crore | ₹102 crore | +9.8% |
| Profit | ₹21.0 crore | ₹20.0 crore | +5.0% |
| Earnings per share | ₹4.61 | ₹4.47 | +3.1% |
| Operating margin | 34.0% | 34.0% | 0.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Vimta Labs' management discussed these results on a call held on 30 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Vimta Labs share price history? Vimta Labs closed at ₹485.55 on 3 November 2026, down 33.1% from ₹725.40 a year earlier (31 October 2025) and up 167.7% over five years. Its highest weekly close since March 2016 was ₹877.20 on 5 September 2025. ### Vimta Labs share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹468.95 | +3.5% |
| 1 month ago · 1 Oct 2026 | ₹583.70 | −16.8% |
| 6 months ago · 30 Apr 2026 | ₹457.15 | +6.2% |
| 1 year ago · 31 Oct 2025 | ₹725.40 | −33.1% |
| 3 years ago · 3 Nov 2023 | ₹217.85 | +122.9% |
| 5 years ago · 4 Nov 2021 | ₹181.40 | +167.7% |
| 10 years ago · 4 Nov 2016 | ₹55.68 | +772.0% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹35.13 | +1,282.2% |
| Highest weekly close since March 2016 · 5 Sep 2025 | ₹877.20 | −44.6% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹29.88 | +1,525.0% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹657.80 | −26.2% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹401.35 | +21.0% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Vimta Labs? 3 Nov 2026: Vimta Labs closed at ₹485.55, up 3.5% on the week and down 16.8% on the month. 30 Oct 2026: Vimta Labs held its results call for July to September 2026. Management guided: FY28 revenue around ₹700 crore implying around 20-25% yearly growth with operating profit 35-36%. ### Earlier

- Results for July to September 2026: Revenue up 9.8% and profit up 5.0% on a year earlier. - 18 Jun 2026: ex-date for a dividend of ₹2 a share. - 13 Jun 2025: Bonus issue: 1 new share for every 1 held (ex-date). ## What dividend does Vimta Labs pay? Vimta Labs paid ₹2 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.41% at the ₹485.55 close on 3 November 2026. The last was a dividend of ₹2 a share, ex-date 18 June 2026. ### Vimta Labs dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 18 Jun 2026 | ₹2 | Dividend |
| 30 May 2025 | ₹2 | Dividend |
| 11 Jul 2024 | ₹2 | Dividend |
| 21 Jun 2023 | ₹2 | Dividend |
| 16 Jun 2022 | ₹2 | Dividend |
| 25 Jun 2021 | ₹2 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Vimta Labs Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 12 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Vimta Labs management say on the latest results call? On the call for July to September 2026, held on 30 October 2026, Vimta Labs' management guided: FY28 revenue around ₹700 crore implying around 20-25% yearly growth with operating profit 35-36%. > “A key milestone during Q2 was the commencement of revenue generation from our biologics services.”
> Harita Vasireddi, on the call for July to September 2026

### What management guided

- FY27 capital spending around ₹80 crore including maintenance ₹45-50 crore with H2 catch-up spread across analytical, preclinical, food and molecule work. - Near-term margins broadly stable with medium-term 100-200 basis points moderation on biologics mix. - Q3-Q4 improvement in large-molecule CRDS, clinical and food volumes on pipeline conversion. - Biologics couple onboardings this quarter with 1:1 return goal by third year, possibly second. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/2661-30-Oct-2026.pdf). (From the call for July to September 2026, 30 October 2026.)

## What to watch in Vimta Labs' next results? When Vimta Labs reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Food sample flows returning to earlier volumes on export-import recovery - check flagged normalisation timeline. - What to check (from the call)
- Food sample flows returning to earlier volumes on export-import recovery - check flagged normalisation timeline. - Biologics additional client wins converting to execution with cross-sales traction - check flagged onboarding momentum. - Sequential revenue acceleration in seasonally stronger half on pharma plus clinical RFP conversion - check pipeline-to-project pass-through. ## Which stock lists is Vimta Labs on? Vimta Labs is not on any of our India lists this week. ## Is Vimta Labs profitable? Vimta Labs Ltd earned ₹21.0 Cr of net profit in the Sep 2026 quarter, +5.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹78.0 Cr. Over 10 years profit has grown 29.2% a year on average. That is 18.8% of the quarter's revenue. The same quarter a year earlier earned ₹20.0 Cr. For the full year, FY26 profit was ₹78.0 Cr (+16.4% on the year before). Why profit moved: revenue changed +9.8% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +3.5% and revenue +11.8%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Vimta Labs make, and is it growing? Vimta Labs Ltd reported ₹112 Cr of revenue in the Sep 2026 quarter, +9.8% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 10 years it has grown 11.4% a year on average. The last full year, FY26, came in at ₹407 Cr. The last four reported quarters add to ₹429 Cr. FY26 revenue was ₹407 Cr, +18.3% on the year before. Recent pace: the last four quarters grew +11.8% on average, against 11.4% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.7%, against +18.4% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +2.5%, against +29.9% a year (rolling over). ## How much of every ₹100 of sales does Vimta Labs keep? Vimta Labs Ltd's operating margin was 34.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 12 years it has been between 14.0% and 35.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed −3.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Vimta Labs' profit turning into cash? Over the last 3 years, 162% of Vimta Labs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹147 Cr of operating cash against ₹78.0 Cr of profit. After ₹99.0 Cr of spending on assets, ₹48.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 162% of profit came in as cash: the cash cycle got 91 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building. ## Where does Vimta Labs' cash go? Vimta Labs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 219 days in FY26, up from 128 days in FY21. It spent ₹255 Cr on assets over the last 3 years. Customers take 95 days to pay, and stock sits for 203 days on average. At FY26 sales of ₹407 Cr, each day of that cycle ties up about ₹1.1 Cr, so roughly ₹244 Cr is tied up in the business at any time. FY26: customers took 95 days to pay and stock sat for 203 days, about 6.7 months of sales sitting as stock, for a full cycle of 219 days, longer than FY21's 128. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 203 days. Customers pay about 95 days after that. Suppliers are paid at 79 days. Together that makes the 219-day cycle. Spending on assets: ₹255 Cr over the last 3 years, against ₹112 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹18.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Vimta Labs' P/E ratio, and how does it compare with its own history? Vimta Labs Ltd's P/E is 26.6×, in the middle of its own history: higher than 54% of past readings. Its usual P/E (the middle reading) is 26.2×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹17.99. Why the multiple is where it is: over the past year earnings per share moved +14.7% while the price moved −33.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +21.8% a year; about +18.7% a year came from earnings growth and about +3.1 percentage points from the multiple (the market paying more); over 10 years the price moved +24.2% a year; about +26.7% a year came from earnings growth and about −2.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Vimta Labs business getting better or worse? Vimta Labs Ltd's business is slowing from a peak. Revenue, profit and EPS growth have slowed sharply (revenue growth from +25.5% at its peak to +11.7% now), while ROCE is still 22.0%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Vimta Labs earn on its capital? Vimta Labs Ltd earned a ROCE of 25% in FY26. That is up from a low of 6% in FY15. Its return on capital used (ROIC) is 7.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 19.2% net margin and 0.72× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 19.2% net margin × 0.72× asset turnover × 1.23× leverage (assets divided by equity) ≈ 17.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 19.1% − 12.0% = +7.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. ## Does Vimta Labs have too much debt? Vimta Labs Ltd has total debt of ₹14.0 Cr against shareholder equity of ₹491 Cr as of Sep 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.08 in FY22 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Vimta Labs shareholding pattern? Foreign institutions raised their stake in Vimta Labs Ltd by 1.8 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 5.1% of the company. Promoters moved −1.3 points over the same period, to 35.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +1.8 points over 8 quarters, to 5.1%; Promoters: −1.3 points over 8 quarters, to 35.6%; Domestic institutions: +0.5 points over 8 quarters, to 0.5%. Why the owners changed: foreign institutions drove it (+1.8 points), with the other side taken by promoters (−1.3 points). They raised their stake step by step. ## How far is Vimta Labs from balance-sheet trouble? For Vimta Labs Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Vimta Labs rank in its industry? 30.1 out of 100, rank 9 of 9 in Diagnostics, with 100% of the evidence available. Vimta Labs Ltd scores 30.1 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 9. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 8.3 + 15.7 + 4.6 + 1.5 = 30.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Vimta Labs compared with? Vimta Labs ranks 9 of 9 Diagnostics companies on the 4-Factor Sector Score, with 30.1 out of 100. 1. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ONEGLOBAL · quiet · Most evidence points up · 81% evidence 70.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 100% · Profit 100% · Operating margin change 4 points · 88% evidence Capital efficiency 14.1/25 · ROCE 87% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 11.6× · PEG 0.45 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -18.5% · 1 year 24.8% · 25% evidence · 0 of 5 weeks ahead Exact sum: 30.1 + 14.1 + 18.5 + 7.5 = 70.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) METROPOLIS · turning · Evidence leans up · 96% evidence 64.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 21.8% · Profit 33.5% · Operating margin change 2 points · 88% evidence Capital efficiency 14.1/25 · ROCE 17.8% · Operating margin 25% · 100% evidence Valuation 13.3/20 · P/E 54.4× · PEG 1.08 · 100% evidence Relative strength 11.5/20 · Lead over its industry 3.2% · Lead over NIFTY 500 11.6% · 1 year 10.8% · 100% evidence · 4 of 12 weeks ahead Exact sum: 25.7 + 14.1 + 13.3 + 11.5 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) THYROCARE · quiet · Evidence leans up · 100% evidence 60.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 22% · Profit 12.6% · Operating margin change 0 points · 100% evidence Capital efficiency 21.3/25 · ROCE 35.4% · Operating margin 33% · 100% evidence Valuation 12.6/20 · P/E 41.5× · PEG 1.1 · 100% evidence Relative strength 4.1/20 · Lead over its industry -6.7% · Lead over NIFTY 500 0.5% · 1 year -2% · 100% evidence · 7 of 12 weeks ahead Exact sum: 22 + 21.3 + 12.6 + 4.1 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Vijaya Diagnostic Centre Ltd](https://www.sectoralpha.in/stocks/vijaya-diagnostic-centre-ltd) VIJAYA · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 20.2% · Profit 23.8% · Operating margin change 4 points · 88% evidence Capital efficiency 16.4/25 · ROCE 20.5% · Operating margin 43% · 100% evidence Valuation 0.3/20 · P/E 79.4× · PEG 4.13 · 100% evidence Relative strength 18.7/20 · Lead over its industry 18.1% · Lead over NIFTY 500 26.8% · 1 year 46.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 16.4 + 0.3 + 18.7 = 59.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) SURAKSHA · breaking out · Evidence leans up · 89% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 23% · Profit 9.4% · Operating margin change 2 points · 88% evidence Capital efficiency 11.7/25 · ROCE 17.3% · Operating margin 35% · 100% evidence Valuation 8.9/20 · P/E 46× · PEG 1.66 · 65% evidence Relative strength 17.2/20 · Lead over its industry 6.7% · Lead over NIFTY 500 15.6% · 1 year -0.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.3 + 11.7 + 8.9 + 17.2 = 57.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Dr Lal Pathlabs Ltd](https://www.sectoralpha.in/stocks/dr-lal-pathlabs-ltd) LALPATHLAB · leader · Evidence leans up · 96% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.4/35 · Revenue 14.3% · Profit 5% · Operating margin change 2 points · 88% evidence Capital efficiency 18.5/25 · ROCE 28% · Operating margin 31% · 100% evidence Valuation 9.3/20 · P/E 56.9× · PEG 1.29 · 100% evidence Relative strength 16.5/20 · Lead over its industry 15.5% · Lead over NIFTY 500 24.4% · 1 year 21.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12.4 + 18.5 + 9.3 + 16.5 = 56.7 · What this means: Relative strength against the index is 24.4%, and revenue and profit growth are weak. 7. [3B Blackbio DX Ltd](https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd) 3BBLACKBIO · breaking out · Evidence leans up · 78% evidence 50.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 54.3% · Profit 14.7% · Operating margin change -27.8 points · 83% evidence Capital efficiency 16.6/25 · ROCE 25.5% · Operating margin 25.4% · 76% evidence Valuation 9.5/20 · P/E 20× · PEG n/a · 50% evidence Relative strength 9.0/20 · Lead over its industry -7% · Lead over NIFTY 500 1.2% · 1 year -5.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 16.6 + 9.5 + 9 = 50.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) KRSNAA · breaking out · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/35 · Revenue 10.3% · Profit 21% · Operating margin change -2 points · 88% evidence Capital efficiency 9.1/25 · ROCE 12.7% · Operating margin 25% · 100% evidence Valuation 18.9/20 · P/E 16.8× · PEG 0.57 · 100% evidence Relative strength 7.9/20 · Lead over its industry n/a · Lead over NIFTY 500 -13.7% · 1 year -35.1% · 25% evidence · 1 of 12 weeks ahead Exact sum: 13.7 + 9.1 + 18.9 + 7.9 = 49.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. Vimta Labs Ltd this page VIMTALABS · quiet · Most evidence points down · 100% evidence 30.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue 11.7% · Profit 2.5% · Operating margin change 0 points · 100% evidence Capital efficiency 15.7/25 · ROCE 25.2% · Operating margin 34% · 100% evidence Valuation 4.6/20 · P/E 26.6× · PEG 2.75 · 100% evidence Relative strength 1.5/20 · Lead over its industry -12.6% · Lead over NIFTY 500 -5.4% · 1 year -33.2% · 100% evidence · 8 of 12 weeks ahead Exact sum: 8.3 + 15.7 + 4.6 + 1.5 = 30.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics](https://www.sectoralpha.in/sectors/diagnostics), all 9 compared on one page. ## Which companies are close to Vimta Labs in size? Vimta Labs is the 5th largest of 9 Diagnostics companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Vijaya Diagnostic Centre, Metropolis Healthcare and Thyrocare Technologies. Just below it: Suraksha Diagnostic, Krsnaa Diagnostics and 3B Blackbio DX. ### Diagnostics companies close in size

1. [Vijaya Diagnostic Centre Ltd](https://www.sectoralpha.in/stocks/vijaya-diagnostic-centre-ltd) ₹14,890 crore
2. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) ₹11,320 crore
3. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) ₹7,263 crore
4. Vimta Labs Ltd ₹2,168 crore
5. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) ₹1,648 crore
6. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) ₹1,634 crore
7. [3B Blackbio DX Ltd](https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd) ₹1,112 crore

[All 9 Diagnostics companies, largest first](https://www.sectoralpha.in/sectors/diagnostics#all-companies)

### Companies close in size in other industries

1. [Talbros Automotive Components Ltd](https://www.sectoralpha.in/stocks/talbros-automotive-components-ltd) ₹2,181 crore · Auto Ancillaries - Axle shafts
2. [Thejo Engineering Ltd](https://www.sectoralpha.in/stocks/thejo-engineering-ltd) ₹2,179 crore · Capital Goods - Others
3. Vimta Labs Ltd ₹2,168 crore
4. [Rajratan Global Wire Ltd](https://www.sectoralpha.in/stocks/rajratan-global-wire-ltd) ₹2,155 crore · Tyres & Tubes
5. [Algoquant Fintech Ltd](https://www.sectoralpha.in/stocks/algoquant-fintech-ltd) ₹2,143 crore · Finance & Investments - Others

## What else do people ask about Vimta Labs? ### What is Vimta Labs's share price today? Vimta Labs Ltd's share price is ₹485.55, −33.1% over the past year. The whole company is worth ₹2,170 Cr on the market. In the last 52 weeks it traded between ₹401 to ₹658; today it is 33% of the way up from the low, 12.5% below its 200-day average (as of 3 November 2026). ### What were Vimta Labs's latest quarterly results? Vimta Labs Ltd reported revenue of ₹112 Cr and net profit of ₹21.0 Cr for the Sep 2026 quarter. Revenue rose 9.8% and profit rose 5.0% compared with a year earlier. Earnings per share were ₹4.61. The operating margin was 34.0%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Vimta Labs's market cap? Vimta Labs Ltd's market capitalisation is ₹2,170 Cr at a share price of ₹485.55. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Vimta Labs performing? Vimta Labs Ltd's share price has been rising for 16 weeks. In its latest quarter, revenue rose 9.8% and profit rose 5.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 3 November 2026). ### Will Vimta Labs's share price go up? This page does not forecast Vimta Labs Ltd's share price. What it shows instead: the share price is ₹485.55, and it has been rising for 16 weeks. Its P/E of 26.6× is higher than 54% of its own last 10 years (as of 3 November 2026). ### Who owns Vimta Labs? Promoters own 35.6% of Vimta Labs Ltd, foreign institutions 5.1%, domestic institutions 0.5% and the public 58.8% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.8 percentage points over 8 quarters (as of 3 November 2026). ### Does Vimta Labs have too much debt? No, Vimta Labs Ltd has little debt: its debt is 0.01× its equity, and its operating profit is more than 100 times its interest bill. FY26 borrowings were ₹3.0 Cr against equity of ₹457 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Vimta Labs in its business cycle? Vimta Labs Ltd's FY26 operating margin was 35.0%, against a 12-year range of 14.0% to 35.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 34.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Vimta Labs story? The main question: yearly earnings per share moved +14.7% while the share price moved −33.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Vimta Labs a stock worth studying right now? What the numbers show: Vimta Labs Ltd's earnings have grown faster than its share price. Earnings per share grew +14.7% in a year while the price moved −33.1%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Vimta Labs share price forecast for 2026? What management itself guided: FY28 revenue around ₹700 crore implying around 20-25% yearly growth with operating profit 35-36%. This is research, not advice. We’re not SEBI-registered.